Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
Stephanie M. Smith(Stanford University), Sonali Chaudhury(Northwestern University), Jeffrey R. Andolina(Golisano Children's Hospital), Lidia Schapira(Palo Alto University), Michael Roth(The University of Texas MD Anderson Cancer Center), Kathleen M. Sakamoto(University of California, Los Angeles), Vandana Sundaram, Nobuko Hijiya(Lurie Children's Hospital), Shiqi Zhang(Stanford University), E. Anders Kolb(Nemours Children's Health System)
Cited by 4
Related Papers
The pediatric preclinical testing program: Description of models and early testing results
|Pediatric Blood & Cancer|2006|486
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
|Journal of Clinical Oncology|2015|383
Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
|JAMA|2007|314
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
|Scientific Reports|2016|263
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach
|CA A Cancer Journal for Clinicians|2022|251